##  [China: NMPA Updates Drug Approval Document Delivery & Publishes Latest Approvals](/index%2ephp/mandate/china-nmpa-updates-drug-approval-document-delivery-publishes-latest-approvals) 

November 11, 2025

China’s NMPA has updated its drug approval document delivery system and published the latest list of approved medicinal products.

**Key highlights:**

- Since **01-Nov-2022**, individuals with administrative penalties can access and print electronic certificates via the NMPA service portal
- Newly approved products as of **11-Nov-2025** include injections, tablets, and other formulations—such as Limonene phosphate injection and Piperacillin sodium and Tazobactam sodium for injection
- The update lists multiple approved products across various manufacturers, supporting transparency in Regulatory activities and public health advancement



[Consult Now](/webform/consult?url=https://preprod.freyrsolutions.com/index%2ephp/mandate/china-nmpa-updates-drug-approval-document-delivery-publishes-latest-approvals)



Source

<https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20251111152524121.html>

 

 

Select Mandate HA

[NMPA](/index%2ephp/mandate-by-ha/nmpa)

 

Select Mandate Function

[Regulatory Affairs](/index%2ephp/mandate-by-function/regulatory-affairs)